US6673901B2
(en)
|
1997-06-12 |
2004-01-06 |
Research Corporation Technologies, Inc. |
Artificial antibody polypeptides
|
US6818418B1
(en)
|
1998-12-10 |
2004-11-16 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
US7115396B2
(en)
|
1998-12-10 |
2006-10-03 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
EP1250463B1
(de)
|
2000-01-24 |
2006-04-05 |
Compound Therapeutics, Inc. |
Sensible und multiplexe diagnostische tests zur proteinanalyse
|
US7022479B2
(en)
|
2000-01-24 |
2006-04-04 |
Compound Therapeutics, Inc. |
Sensitive, multiplexed diagnostic assays for protein analysis
|
EP2385067A1
(de)
|
2000-07-11 |
2011-11-09 |
Research Corporation Technologies, Inc. |
Künstliche Antikörperpolypeptide
|
WO2002020565A2
(en)
|
2000-09-08 |
2002-03-14 |
Universität Zürich |
Collections of repeat proteins comprising repeat modules
|
JP2004526419A
(ja)
*
|
2000-10-16 |
2004-09-02 |
フィロス インク. |
抗体模倣物および他の結合タンパク質のためのタンパク質骨格
|
IL155812A0
(en)
*
|
2000-12-07 |
2003-12-23 |
Lilly Co Eli |
Glp-1 fusion proteins
|
CA2443332A1
(en)
*
|
2001-04-04 |
2002-10-17 |
University Of Rochester |
.alpha..nu..beta.3 integrin-binding polypeptide monobodies and their use
|
AU2002351896A1
(en)
*
|
2001-12-11 |
2003-06-23 |
Ablynx N.V. |
Method for displaying loops from immunoglobulin domains in different contexts
|
EP1507556B1
(de)
|
2002-05-02 |
2016-07-27 |
Wyeth Holdings LLC |
Calicheamicin-derivat-trägerkonjugate
|
AU2003243436A1
(en)
|
2002-06-06 |
2003-12-22 |
Shohei Koide |
Reconstituted polypeptides
|
US7083948B1
(en)
|
2002-12-24 |
2006-08-01 |
Immunex Corporation |
Polypeptide purification reagents and methods for their use
|
PT2382990E
(pt)
|
2003-04-30 |
2014-12-29 |
Univ Zuerich |
Método para tratamento do cancro usando uma imunotoxina
|
GB0407315D0
(en)
|
2003-07-15 |
2004-05-05 |
Cambridge Antibody Tech |
Human antibody molecules
|
KR20060129246A
(ko)
|
2003-12-05 |
2006-12-15 |
컴파운드 쎄라퓨틱스, 인크. |
타입 2 혈관 내피 성장 인자 수용체의 억제제
|
HUE042689T2
(hu)
|
2005-02-08 |
2019-07-29 |
Genzyme Corp |
TGFbéta elleni antitestek
|
PL2423230T3
(pl)
|
2006-03-27 |
2013-10-31 |
Medimmune Ltd |
Element wiążący dla receptora GM-CSF
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
WO2008019290A2
(en)
|
2006-08-04 |
2008-02-14 |
Astrazeneca Ab |
Human antibodies to erbb 2
|
PL2068921T3
(pl)
|
2006-10-19 |
2014-12-31 |
Csl Ltd |
Przeciwciała o dużym powinowactwie będące antagonistami receptora alfa1 interleukiny 13
|
CA2670471A1
(en)
|
2006-11-22 |
2008-06-05 |
Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
US20100144599A1
(en)
|
2007-02-02 |
2010-06-10 |
Bristol-Myers Squibb Company |
Vegf pathway blockade
|
AR065368A1
(es)
|
2007-02-15 |
2009-06-03 |
Astrazeneca Ab |
Anticuerpos para moleculas de ige
|
MX2009010639A
(es)
|
2007-04-02 |
2009-10-23 |
Philogen Spa |
Nuevo antigeno asociado con la neovasculatura de metastasis tumoral.
|
CA2683559C
(en)
|
2007-04-13 |
2019-09-24 |
Dana Farber Cancer Institute, Inc. |
Methods for treating cancer resistant to erbb therapeutics
|
US8492328B2
(en)
|
2007-05-17 |
2013-07-23 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
|
KR101781638B1
(ko)
|
2007-07-25 |
2017-09-25 |
필로겐 에스.피.에이. |
종양 전이의 신생혈관과 관련된 피브리노겐의 ed-a 항원
|
CN101918443B
(zh)
|
2007-10-30 |
2013-07-17 |
菲洛根股份公司 |
一种与类风湿性关节炎相关的抗原
|
BRPI0818810A2
(pt)
|
2007-10-31 |
2014-10-29 |
Medimmune Llc |
Esqueletos d polipeptídeo recombinante e multimérico, molécula de ácido n ucleico isolado, vetor de expressão, célula hospedeira, biblioteca de exibição de polipeptídeo, coleção de moléculas de ácido nucleico isolado, métodos para obter um esqueleto de polipeptídeo e pelo menos dois esqueletos, para detectar um composto em uma amostra, para capturar um composto em uma amostra, para prevenir, tratar, controlar ou melhorar uma doença, para diagnose ou formação de imagem de uma doença para purificar e produzir um esqueleto, para ensaiar ou detectar a ligação de um esqueleto a um alvo, para usar o esqueleto e para prevenir, tratar, melhora ou controlar câncer, composição estéril, isenta de pirógeno, composição farmacêutica, e, processo escalável.
|
RU2490278C2
(ru)
|
2007-12-21 |
2013-08-20 |
Медиммун Лимитед |
ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
WO2009083804A2
(en)
*
|
2007-12-27 |
2009-07-09 |
Novartis Ag |
Improved fibronectin-based binding molecules and their use
|
JP2011517314A
(ja)
*
|
2008-02-14 |
2011-06-02 |
ブリストル−マイヤーズ スクイブ カンパニー |
Egfrに結合する操作されたタンパク質に基づく標的化された治療薬
|
EP2439212B1
(de)
*
|
2008-05-02 |
2016-12-21 |
Novartis AG |
Verbesserte Bindemoleküle auf Fibronectin-Basis und ihre Verwendung
|
EP2799448A1
(de)
|
2008-05-22 |
2014-11-05 |
Bristol-Myers Squibb Company |
Polyvalente Proteine mit Fibronectin-Gerüstdomänen
|
WO2010032060A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune Llc |
Antibodies directed to dll4 and uses thereof
|
AU2009308935B2
(en)
|
2008-10-31 |
2015-02-26 |
Janssen Biotech, Inc. |
Fibronectin type III domain based scaffold compositions, methods and uses
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
AU2009327189B2
(en)
|
2008-12-16 |
2012-09-06 |
Novartis Ag |
Yeast display systems
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
EP2379116B1
(de)
|
2009-01-07 |
2015-08-26 |
Philogen S.p.A. |
Mit endometriose assoziierte antigene
|
US8067201B2
(en)
|
2009-04-17 |
2011-11-29 |
Bristol-Myers Squibb Company |
Methods for protein refolding
|
EP2947096B1
(de)
|
2009-08-05 |
2018-11-28 |
Philogen S.p.A. |
Abzielung auf die neovaskulatur des knochenmarks
|
WO2011020033A2
(en)
*
|
2009-08-13 |
2011-02-17 |
Massachusetts Institute Of Technology |
Engineered proteins including mutant fibronectin domains
|
EP2494070A2
(de)
|
2009-10-30 |
2012-09-05 |
Bristol-Myers Squibb Company |
Verfahren zur krebsbehandlung bei patienten mit igf-1r-hemmer-resistenz
|
ES2691717T3
(es)
|
2009-10-30 |
2018-11-28 |
Novartis Ag |
Bibliotecas universales del dominio de unión del lado inferior de tipo iii de la fibronectina de tipo III
|
MX343747B
(es)
|
2009-11-24 |
2016-11-22 |
Medimmune Ltd |
Agentes de union diana contra b7-h1.
|
SG181901A1
(en)
|
2009-12-23 |
2012-08-30 |
4Antibody Ag |
Binding members for human cytomegalovirus
|
EP2556086B1
(de)
|
2010-04-09 |
2015-03-04 |
Amgen Inc. |
Btnl9-proteine, nukleinsäuren sowie antikörper und ihre verwendung
|
EP2558495B1
(de)
|
2010-04-13 |
2019-07-17 |
MedImmune, LLC |
Trail r2-spezifische multimere gerüste
|
KR101863033B1
(ko)
|
2010-04-30 |
2018-06-01 |
얀센 바이오테크 인코포레이티드 |
안정화된 파이브로넥틴 도메인 조성물, 방법 및 용도
|
TW201138808A
(en)
|
2010-05-03 |
2011-11-16 |
Bristol Myers Squibb Co |
Serum albumin binding molecules
|
JP6023703B2
(ja)
|
2010-05-26 |
2016-11-09 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
|
US20130330352A1
(en)
|
2010-09-01 |
2013-12-12 |
Genzyme Corporation |
Treatment of myocardial infarction using tgf beta antagonists
|
AU2011347354A1
(en)
|
2010-12-20 |
2013-08-01 |
Medimmune Limited |
Anti-IL-18 antibodies and their uses
|
WO2012110824A1
(en)
|
2011-02-18 |
2012-08-23 |
Astrazeneca Ab |
Binding agents with specificity for a nucleic acid modification
|
EP3415528B1
(de)
|
2011-04-13 |
2021-05-26 |
Bristol-Myers Squibb Company |
Fc-fusionsproteine mit neuartigen linkern oder anordnungen
|
US20140187488A1
(en)
|
2011-05-17 |
2014-07-03 |
Bristol-Myers Squibb Company |
Methods for maintaining pegylation of polypeptides
|
ES2848531T3
(es)
|
2011-05-17 |
2021-08-10 |
Bristol Myers Squibb Co |
Métodos mejorados para la selección de proteínas de unión
|
EP2548891A1
(de)
|
2011-07-18 |
2013-01-23 |
Universiteit Maastricht |
Humaner monoklonaler Antikörper gegen die Gamma-Untereinheit des Acetylcholin-Rezeptors zur Verwendung bei der Behandlung von Rhabdomyosarkom
|
IL277891B2
(en)
|
2011-09-27 |
2024-01-01 |
Janssen Biotech Inc |
Protein scaffolds based on type III fibronectin repeats with alternative binding surfaces
|
AU2012322991B2
(en)
|
2011-10-10 |
2018-02-15 |
Medimmune Limited |
Treatment for rheumatoid arthritis
|
SG10201707813YA
(en)
|
2011-10-11 |
2017-11-29 |
Medimmune Llc |
Cd40l-specific tn3-derived scaffolds and methods of use thereof
|
WO2013056069A1
(en)
|
2011-10-13 |
2013-04-18 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
CN104053670A
(zh)
|
2011-10-31 |
2014-09-17 |
百时美施贵宝公司 |
具有降低的免疫原性的纤连蛋白结合域
|
ES2753135T3
(es)
|
2012-05-07 |
2020-04-07 |
Allergan Inc |
Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
|
EP2875046B1
(de)
|
2012-07-19 |
2020-02-26 |
Amgen Inc. |
Humane btnl3-proteine, nukleinsäuren sowie antikörper und verwendungen davon
|
ES2727453T3
(es)
|
2012-09-13 |
2019-10-16 |
Bristol Myers Squibb Co |
Proteínas de dominio de armazón a base de fibronectina que se unen a miostatina
|
CN104768563B
(zh)
|
2012-10-03 |
2020-02-28 |
菲罗根股份公司 |
与炎性肠病有关的抗原
|
CA2886987C
(en)
|
2012-11-08 |
2022-07-12 |
Eleven Biotherapeutics, Inc. |
Il-6 antagonists and uses thereof
|
US20150361159A1
(en)
|
2013-02-01 |
2015-12-17 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
ES2689372T3
(es)
|
2013-02-06 |
2018-11-13 |
Bristol-Myers Squibb Company |
Proteínas de dominio de fibronectina tipo III con solubilidad mejorada
|
US10065987B2
(en)
|
2013-02-12 |
2018-09-04 |
Bristol-Myers Squibb Company |
High pH protein refolding methods
|
EP2968587A2
(de)
|
2013-03-13 |
2016-01-20 |
Bristol-Myers Squibb Company |
Serumalbumingebundene fibronectin-gerüstdomänen oder daran bindendes element
|
AU2014229549B2
(en)
*
|
2013-03-14 |
2018-11-01 |
The Governing Council Of The University Of Toronto |
Scaffolded peptidic libraries and methods of making and screening the same
|
GB201307501D0
(en)
|
2013-04-25 |
2013-06-12 |
Univ Aberdeen |
Anti-fungal antibody molecules and uses thereof
|
JP6591437B2
(ja)
|
2014-03-20 |
2019-10-16 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
血清アルブミン結合フィブロネクチンiii型ドメイン
|
MX371403B
(es)
|
2014-03-20 |
2020-01-29 |
Bristol Myers Squibb Co |
Moleculas de andamiaje a base de fibronectina estabilizada.
|
GB201407852D0
(en)
|
2014-05-02 |
2014-06-18 |
Iontas Ltd |
Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
|
NZ731090A
(en)
|
2014-11-07 |
2024-03-22 |
F Hoffmann La Roche Ltd |
Improved il-6 antibodies
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
US10793642B2
(en)
|
2014-12-11 |
2020-10-06 |
Inbiomotion S.L. |
Binding members for human c-MAF
|
CN107849142B
(zh)
|
2015-05-15 |
2022-04-26 |
综合医院公司 |
拮抗性抗肿瘤坏死因子受体超家族抗体
|
US10766946B2
(en)
|
2015-09-23 |
2020-09-08 |
Bristol-Myers Squibb Company |
Fast-off rate serum albumin binding fibronectin type III domains
|
JP6951340B2
(ja)
|
2015-09-23 |
2021-10-20 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
グリピカン−3結合フィブロネクチンベース足場分子
|
EP3433281A1
(de)
|
2016-03-21 |
2019-01-30 |
Elstar Therapeutics, Inc. |
Multispezifische und multifunktionelle moleküle und verwendungen davon
|
CN109789195A
(zh)
|
2016-04-13 |
2019-05-21 |
维维雅生物技术公司 |
离体bite激活的t细胞
|
CA3036564A1
(en)
|
2016-09-23 |
2018-03-29 |
Elstar Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
WO2018111976A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Pd-l1 binding fibronectin type iii domains
|
BR112019012154A2
(pt)
|
2016-12-14 |
2019-11-12 |
Janssen Biotech Inc |
domínios do tipo iii da fibronectina de ligação a cd8a
|
US10611823B2
(en)
|
2016-12-14 |
2020-04-07 |
Hanssen Biotech, Inc |
CD137 binding fibronectin type III domains
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
CA3058944A1
(en)
|
2017-04-19 |
2018-10-25 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
WO2018201047A1
(en)
|
2017-04-28 |
2018-11-01 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
JP2020522254A
(ja)
|
2017-05-31 |
2020-07-30 |
エルスター セラピューティクス, インコーポレイテッド |
骨髄増殖性白血病(mpl)タンパク質に結合する多特異性分子およびその使用
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
US20200377571A1
(en)
|
2017-12-08 |
2020-12-03 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
EP3502139A1
(de)
|
2017-12-19 |
2019-06-26 |
Philogen S.p.A. |
Antikörper gegen tumorantigene
|
US20210238280A1
(en)
|
2018-03-14 |
2021-08-05 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
US11845797B2
(en)
|
2018-07-03 |
2023-12-19 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
CN113164777A
(zh)
|
2018-09-27 |
2021-07-23 |
马伦戈治疗公司 |
Csf1r/ccr2多特异性抗体
|
GB2599229B
(en)
|
2019-02-21 |
2024-04-24 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to calreticulin and uses thereof
|
AU2020226904A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
SG11202108955QA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to nkp30 and uses thereof
|
EP3927744A1
(de)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunktionelle moleküle, die an t-zell-verwandte krebszellen binden, und verwendungen davon
|
CN114127112A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
|
EP4045061A4
(de)
|
2019-10-14 |
2024-04-17 |
ARO Biotherapeutics Company |
Cd71-bindende fibronectin-typ iii-domänen
|
WO2021076574A2
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Fn3 domain-sirna conjugates and uses thereof
|
EP4084821A4
(de)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
An cd33 bindende multifunktionsmoleküle und ihre verwendungen
|
JP2023523011A
(ja)
|
2020-04-24 |
2023-06-01 |
マレンゴ・セラピューティクス,インコーポレーテッド |
T細胞関連のがん細胞に結合する多機能性分子およびその使用
|
AU2021331076A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
JP2023542080A
(ja)
|
2020-08-26 |
2023-10-05 |
マレンゴ・セラピューティクス,インコーポレーテッド |
カルレティキュリンに結合する多機能性分子およびその使用
|
AU2021333779A1
(en)
|
2020-08-26 |
2023-04-13 |
Marengo Therapeutics, Inc. |
Methods of detecting TRBC1 or TRBC2
|
BR112023020832A2
(pt)
|
2021-04-08 |
2023-12-19 |
Marengo Therapeutics Inc |
Moléculas multifuncionais ligadas a tcr e seus usos
|
CA3229003A1
(en)
|
2021-08-25 |
2023-03-02 |
Kothai Nachiar Devi PARTHIBAN |
Preparation of libraries of protein variants expressed in eukaryotic cells
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2024088921A1
(en)
|
2022-10-24 |
2024-05-02 |
F. Hoffmann-La Roche Ag |
Predicting response to il-6 antagonists
|
WO2024118866A1
(en)
|
2022-12-01 |
2024-06-06 |
Modernatx, Inc. |
Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
|